Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051604 | 0.88 | CSF1R (0.48) | CSF1RRAF1FGFR1KDRTEK | |
| SCHEMBL2046179 | 0.86 | CSF1R (0.53) | CSF1R | |
| SCHEMBL15552508 | 0.85 | CSF1R (0.50) | CSF1RRAF1FGFR1KDRTEK | |
| SCHEMBL2048851 | 0.84 | CSF1R (0.44) | CSF1RRAF1FGFR1KDRTEK | |
| SCHEMBL2051584 | 0.83 | CSF1R (0.42) | CSF1RRAF1FGFR1KDRTEK | |
| SCHEMBL2049189 | 0.82 | CSF1R (0.52) | CSF1R | |
| SCHEMBL2048883 | 0.82 | CSF1R (0.51) | CSF1R | |
| SCHEMBL2046393 | 0.81 | CSF1R (0.49) | CSF1RRAF1FGFR1KDRTEK | |
| SCHEMBL9941735 | 0.81 | CSF1R (0.41) | CSF1RRAF1FGFR1KDRTEK | |
| SCHEMBL2048520 | 0.81 | KDM4E (0.43) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102822170-B | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2014-12-10 | — | — | CN | disclosed |
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2516433-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-05-21 | — | — | EP | disclosed |
| WO-2014003483-A1 | FUSED PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON FMS KINASES | HANMI PHARM. CO., LTD. (KR) | 2014-01-03 | — | — | WO | disclosed |
| CN-102822170-A | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2012-12-12 | — | — | CN | disclosed |
| EP-2516433-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | Array Biopharma, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | CSF1R 17/4885RAF1 500/4885FGFR1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.